Evolving management of patients treated by drug-eluting stent: prevention of late events

Cardiovasc Revasc Med. 2014 Mar;15(2):100-8. doi: 10.1016/j.carrev.2014.01.012. Epub 2014 Jan 30.

Abstract

Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared with BMS. However, this benefit is mainly evident in the first year of follow-up. Indeed, DES-related events may extend over this time, due to late events (late ISR and/or very late stent thrombosis). Prevention of late failure of DES may become a specific therapeutic target.

Keywords: Drug-eluting stent; In-stent restenosis; Late events; Prevention; Stent thrombosis.

Publication types

  • Review

MeSH terms

  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / therapy*
  • Coronary Restenosis / etiology
  • Coronary Restenosis / prevention & control*
  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / prevention & control*
  • Drug-Eluting Stents*
  • Humans
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / instrumentation*
  • Prosthesis Design
  • Risk Factors
  • Time Factors
  • Treatment Outcome